Palliative treatment in myelofibrosis (MF) includes transfusion support, JAK2 inhibitors, involved field radiotherapy and splenectomy. To assist in selecting patients who are likely to benefit from splenectomy, we looked into risk factors for postsplenectomy survival, in 120 consecutive cases (median age 66 years); at the time of splenectomy, 61% displayed red cell transfusion need, 49% platelet count <100 3 10(9)/L, 25% leukocyte count >25 3 10(9)/L, 60% constitutional symptoms and 13% circulating blasts 5%; dynamic international prognostic scoring system risk categories were 21% high, 55% intermediate-2, 21% intermediate-1 and 3% low. Among informative cases, karyotype was abnormal in 60% and driver mutational status was JAK2 75%, CALR 15%, MPL 4% and triple-negative 6%. At median follow-up of 1.3 years, from time of splenectomy, 95 (79%) deaths and 30 (25%) leukemic transformations were recorded. Median postsplenectomy survival was 1.5 years; in multivariable analysis, survival was adversely affected by age >65 years, transfusion need, leukocyte count >25 3 10(9)/L and circulating blasts 5%; these variables were subsequently used to devise an HR-weighted scoring system with high (3-4 risk factors), intermediate (2 risk factors) and low (0-1 risk factors) risk categories; the corresponding postsplenectomy median survivals were 0.3 (HR 5.9, 95% CI 3.2-11.0), 1.3 (HR 2.9, 95% CI 1.8-4.6) and 2.9 years. Postsplenectomy survival was not affected by driver mutational status or occurrence of leukemic transformation. Leukemia-free survival was predicted by very high risk karyotype. The observations from the current study might help identify appropriate candidates for splenectomy in MF.
| I N TR ODU C TI ON
Current drug therapy in myelofibrosis (MF), including the use of JAK2 inhibitors, is mostly palliative and does not modify the natural history of the disease 1 ; the latter might be accomplished by allogeneic stem cell transplant (ASCT). 2 Other treatment modalities with palliative value in MF include red cell transfusion support, involved field radiotherapy, and splenectomy. 3 Indications for splenectomy in MF include drugrefractory symptomatic splenomegaly, frequent transfusion need, refractory thrombocytopenia and complications from portal hypertension. 4, 5 The salutary effects of splenectomy in MF include symptomatic relief and improvement in anemia and thrombocytopenia. Complications following splenectomy for MF include perioperative bleeding, infections and thrombosis, including splanchnic vein thrombosis. In addition, some patients experience postsplenectomy increase in the severity of hepatomegaly, thrombocytosis or leukocytosis and an increase in circulating blast count.
Extramedullary hematopoiesis (EMH) is the main cause of splenomegaly in MF. 6 Historically, splenectomy in MF and related disorders was resisted because of the assumption that it represented the only blood forming tissue. 7 The palliative value of splenectomy in MF was recognized as early as the 1950s. 8 In our first report of 223 patients splenectomized between 1976 and 1996, at the Mayo Clinic, 5 perioperative mortality was approximately 9% and 30% of patients experienced perioperative complications including 15% bleeding, 9% infections and 7% thrombosis. In the particular study, 5 the majority of the patients experienced improvement in constitutional symptoms and 30% of transfusion-dependent patients became transfusion-independent. Similar observations were made in our subsequent expanded cohort of 314 patients. 9 The primary P values less than 0.05 were considered significant. All analyses were conducted using the Stat View (SAS Institute, Cary, NC, USA). Table 1 
| R E SU LTS

| Clinical and laboratory features at time of splenectomy
| D I SCUSSION
The current document summarizes our contemporary experience with splenectomy in MF. The observed spectrum of complications and treatment response pattern were similar to those cited in our previous reports. 5, 9 More importantly, the current study identified older age at time of splenectomy, red cell transfusion need, marked leukocytosis Alternative treatment options for MF patients considered unlikely to benefit from splenectomy include higher dose JAK inhibitor therapy, conventional chemotherapy and involved field radiation therapy. 3 Unfortunately, such measures have limited value that is often transient and associated with protracted myelosuppression. Therefore, it might be prudent to consider splenectomy earlier than later in patients with progressive splenomegaly that is not responding well to drug therapy. In this regard, the observations from the current study do not support the concern by some that splenectomy in MF might deprive patients of an effective blood production site; an increase in ; the first concern is partially addressed by the current availability of effective drugs for organomegaly, 15, 16 while the apparent association with "leukemic transformation" is more likely a reflection of postsplenectomy redistribution of circulating blasts, rather than true clonal evolution, without impact on overall survival. 5 Furthermore, the observed association between VHR karyotype and postsplenectomy leukemic transformation points to underlying disease biology, rather than splenectomy per se, as the culprit for the particular complication.
Splenectomy is also sometimes considered as a preparative measure before ASCT, to improve post-transplant recovery of counts. Published reports in this regard have not been definitive, regarding the advisability of such practice, but agree on its value in terms of faster platelet and granulocyte recovery 17, 18 ; these studies have also indicated the lack of detrimental effect on the risk of disease relapse or nonrelapse mortality and morbidity. What is not currently clear is whether or not pretransplant splenectomy in MF results in superior or inferior post-transplant survival. The same can be said regarding other pretransplant treatment modalities that target the spleen, including low dose radiation therapy 19 and use of JAK2 inhibitors. 20 In our opinion, it is important to be transparent with the facts and avoid personal bias when presenting these options to the patient and also consider the presence of absence of risk factors that might predict successful outcome associated with each treatment strategy.
